Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients.
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Belatacept (Primary) ; Basiliximab; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
- Indications Liver transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 02 Apr 2022 This trial has been completed in France (End Date: 2 May 2011) according to European Clinical Trials Database record.
- 03 Jul 2012 Planned number of patients changed from 250 to 275 as reported by European Clinical Trials Database.
- 21 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.